A Phase 4 interventional study of Tacrolimus and Tacrolimus in Kidney Disease, Chronic, Transplant Recipient (Kidney) and Immunosuppression, sponsored by Instituto de Investigación Hospital Universitario La Paz. Recruiting at 1 site in Spain. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by Instituto de Investigación Hospital Universitario La Paz · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Renal Insufficiency, Chronic with a site in Spain — 38 open to participants now, 55 under way, 23 of them phase 3. Renal Insufficiency, Chronic · Spain.
Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, this one is the 106th largest by planned enrollment of the 154 interventional ones that give a count, is one of 13 that started in 2025, is one of 14 in phase 4, reaches primary completion later than 14 of the 54 other live ones, and was the 155th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →38 of the 188 studies in Renal Insufficiency, Chronic with a site in Spain are open now. Recruiting first, the newest first:
Cardenal Herrera University · Sites in Spain
Ages 18–85
AstraZeneca · Sites in Spain, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Spain, United States, China and 5 more countries
Ages 2–18
Vifor Fresenius Medical Care Renal Pharma · Sites in Spain, China, Greece and 4 more countries
Ages 12–18
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 34 · Phase 3 80 · Phase 4 14
First in 1998; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 252 across the 154 interventional studies, 397 across the 34 observational. Of the 122 that completed or were terminated, 68 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 188 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigación Hospital Universitario La Paz is the lead sponsor of 104 studies on the registry; 14 are open to participants now.
Instituto de Investigación Hospital Universitario La Paz has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
13 of the studies in Renal Insufficiency, Chronic with a site in Spain that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06578078Phase 3Fundación para la Investigación del Hospital Clínico de ValenciaA Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | 2026-12-30 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
Add all 13 to your calendar (.ics) → With an account.
Among the 188 studies in Renal Insufficiency, Chronic with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective, cost-effective, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol.
This is a nation-wide, multicentre, randomised, controlled, and adaptive phase IV clinical trial that aims to assess the effectiveness and cost-effective of pre-emptive pharmacogenetic testing strategies, including those impacted by genetic variants associated with adverse drug reactions (ADRs) or limited efficacy. The clinical trials will evaluate the effective and cost-effective of pre-emptive genotyping by defining a drug-gene-endpoint triad. Study subjects will be pre-emptively genotyped and, if found to have an actionable gene variant, randomly allocated to either a test group where guideline-based treatment modifications will be initiated or a control group that will be managed according to healthcare provider standard of care (SoC). Subsequently, subjects will be prospectively followed at prespecified timepoints. Detailed information on drug-gene-endpoint triads, allocation schemes, and follow-up visits will be provided in each of the subprotocols. A Data Monitoring Committee (DMC), composed of physician experts, will be appointed for each nested trial to review the data on an ongoing basis, ensuring the safety of participants and scientific validity of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this control group will receive treatment with any formulation of Tacrolimus authorized and commercialized in Spain. They will be administered tacrolimus according to clinical practice and the drug's product labeling.
Drug: Tacrolimus
Participants in this experimental group will receive treatment with any formulation of Tacrolimus authorized and commercialized in Spain. They will be administered the specific dosage of tacrolimus recommended by the Clinical Pharmacogenetics Consortium's genotype guidelines, utilizing the patient's pharmacogenetic information and characteristics.
Drug: Tacrolimus
Tacrolimus at the dosage reccomended by the "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing" based on the subjects pharmacogenetic phenotype.
Subject allocated to this arm will receive tacrolimus according to clinical practice and the drug's product labelling. These subject will not receive a personalised dose based on their pharmacogenetic phenotype.
Tacrolimus concentrations levels
Number and percentage of patients achieving tacrolimus target plasma concentrations at visit 3. Tacrolimus concentrations levels at day 4 (+/-1d) will be the effectiveness surrogate outcome. It will be considered therapeutic range levels between 7-10 ng/ml.
Time frame: 4 days
Incremental cost-effectiveness ratio (ICER)
Cost-effectiveness ratio that divides the differences in costs between both treatments by the difference in effectiveness between both treatments.
Time frame: Though study completion, on average 18 months
Number and percentage of patients with transplant rejection.
Transplant rejection will be considered if there is histological confirmation and/or the patient initiates any type of therapy aimed at treating rejection (e.g. corticosteroids).
Time frame: Though study completion, on average 18 months
Rate of AE associated to treatment.
All adverse events associated to tacrolimus will be recorded during the study
Time frame: Though study completion, on average 18 months
Number and percentage of patients achieving tacrolimus target plasma concentrations at visit 4, 5 and 6.
Time frame: Week 4, 15 and 26
Healthcare expenditure related to predefined events of interest
Any costs made as a result of an AE
Time frame: Though study completion, on average 18 months
Incidence of discontinuation or treatment modification
Incidence of discontinuation or treatment modification due to lack of effective related to the drug of inclusion.
Time frame: Though study completion, on average 18 months
Novel prognostic and predictive genetic biomarkers of tacrolimus safety and effectiveness
All participants DNA sample will be susceptible of deep sequencing analysis assessed trough techniques only available at Nation Centre of Oncological Investigations (CNIO) and genome-wide association studies when applicable
Time frame: Though study completion, on average 18 months
Identification of new actionable genes/relevant polymorphisms within the predefined population subsets
Time frame: Though study completion, on average 18 months
Plan to share: Yes — A copy of the database of data collected during the clinical trial will be attached as an appendix to the publication resulting from this clinical trial.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data will be available at the same time as the results will be published, and will be kept available to everyone without any time limit.
Access criteria: Data will be available indefinitely on the publisher's website, as long as it is kept by the Publisher, for anyone who wishes to access the data, for non-commercial purposes.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Oct 2026, 15 months after the start.
Of 101 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 65. This study's planned 15 months is below that.
Counting every sponsor, half of 117 studies reached it within 43 months; a quarter within 22 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tacrolimus
Renal Insufficiency, Chronic →
Instituto de Investigación Hospital Universitario La Paz →